RT Journal Article
SR Electronic
A1 Vinall, Maria
T1 Otamixaban May Reduce the Risk of Ischemic Events in Patients with NSTE-ACS
JF MD Conference Express
YR 2009
FD SAGE Publications
VO 9
IS 4
SP 20
OP 20
DO 10.1177/155989770904012
UL http://mdc.sagepub.com/content/9/4/20.1.abstract
AB Results from the phase 2 Study Program to Evaluate the Prevention of Ischemia with Direct Xa inhibition [SEPIA-ACS1 TIMI 42; NCT00317395] study provided promising data that otamixaban, an intravenous direct Factor Xa inhibitor, at intermediate doses may be associated with a lower risk of ischemic events with similar bleeding compared with the current standard of care in patients with non-ST elevation acute coronary syndromes (NSTE-ACS) [Sabatine MS et al. Lancet 2009].